Enlivex Therapeutics Reports Positive Phase 2b Data
Ticker: ENLV · Form: 6-K · Filed: Aug 18, 2025 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial, data-release, drug-development
TL;DR
Enlivex's Allocetra shows statistically significant survival benefit in Phase 2b trial.
AI Summary
On August 18, 2025, Enlivex Therapeutics Ltd. announced three-month topline data from its Phase 2b clinical trial for Allocetra. The data showed a statistically significant improvement in overall survival (OS) for patients treated with Allocetra compared to placebo in the study population.
Why It Matters
Positive clinical trial results for Allocetra could lead to regulatory approval and commercialization, potentially impacting treatment options for patients and the company's market position.
Risk Assessment
Risk Level: medium — Clinical trial results are promising but require further validation in larger trials and regulatory approval, which carry inherent risks.
Key Numbers
- Phase 2b — Clinical Trial Phase (The stage of the trial reporting topline data)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Filer of the report and developer of Allocetra
- Allocetra (drug) — Investigational therapy in Phase 2b trial
- August 18, 2025 (date) — Date of the press release announcing topline data
FAQ
What specific disease is Allocetra being tested for in this Phase 2b trial?
The provided text does not specify the disease being treated in the Phase 2b trial.
What was the primary endpoint of the Phase 2b trial?
The provided text mentions topline data and statistically significant improvement in overall survival, but does not explicitly state the primary endpoint.
What is the statistical significance level (p-value) for the observed overall survival improvement?
The filing states a 'statistically significant improvement' but does not provide the specific p-value.
When is Enlivex Therapeutics Ltd. expected to release further details or initiate the next phase of trials?
The filing does not provide information on future timelines for data release or trial progression.
What is the previous name of Enlivex Therapeutics Ltd.?
The company was formerly known as Bioblast Pharma Ltd.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-08-18 07:47:26
Filing Documents
- ea0253587-6k_enlivex.htm (6-K) — 10KB
- ea025358701ex99-1_enlivex.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-077714.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: August 18, 2025 2